Modality
Radioligand
MOA
TYK2i
Target
B7-H3
Pathway
Notch
EpilepsyLGS
Development Pipeline
Preclinical
~Jun 2021
→ ~Sep 2022
Phase 1
~Dec 2022
→ ~Mar 2024
Phase 2
Jun 2024
→ Nov 2026
Phase 2Current
NCT07114974
2,921 pts·LGS
2024-06→2026-11·Terminated
2,921 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-11-087mo awayPh3 Readout· LGS
Trial Timeline
Q3Q42025Q2Q3Q42026Q2Q3Q4
P2/3
Termina…
Catalysts
Ph3 Readout
2026-11-08 · 7mo away
LGS
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07114974 | Phase 2/3 | LGS | Terminated | 2921 | LiverFat |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Nidasacituzumab | Eli Lilly | Approved | CFTR | |
| LLY-4358 | Eli Lilly | Phase 3 | B7-H3 | |
| Lisonaritide | Eli Lilly | Phase 3 | IL-13 | |
| Ceviglumide | Roche | NDA/BLA | B7-H3 | |
| MRK-2473 | Merck & Co | Phase 1/2 | Nectin-4 | |
| Zorisotorasib | AstraZeneca | Phase 1 | WRN | |
| SNY-9600 | Sanofi | NDA/BLA | B7-H3 | |
| SNY-8628 | Sanofi | NDA/BLA | B7-H3 | |
| SNY-9073 | Sanofi | Phase 2 | B7-H3 | |
| NVO-7840 | Novo Nordisk | Phase 2/3 | B7-H3 |